Agonist News and Research

RSS

The importance of the endocannabinoid-system

Cannabis (marijuana) is the most widely produced plant-based illicit drug worldwide and the illegal drug most frequently used in Europe.

15 Oct 2007

How does the opioid system work?

The opioid system controls pain, reward and addictive behaviors. Opioids exert their pharmacological actions through three opioid receptors, mu, delta and kappa whose genes have been cloned (Oprm, Oprd1 and Oprk1, respectively).

15 Oct 2007

Children with asthma missing out on best drug treatment in the UK

Children with asthma are missing out on the best drug treatment for their disease, because family doctors are ignoring prescribing guidelines, suggests research published ahead of print in the Archives of Disease in Childhood.

4 Sep 2007

GSK supports emphasis on asthma control in treatment guidelines

New asthma treatment guidelines issued today urge healthcare professionals to first assess the severity of a patient's asthma to determine and administer initial treatment and then obtain regular assessments of the patient's level of asthma control.

29 Aug 2007

Specific antagonism lowers blood pressure

High blood pressure (hypertension) is associated with an increased risk of heart attack and stroke, and the frequent use of drugs known as NSAIDs, for example to treat individuals with rheumatoid arthritis, can cause hypertension.

17 Aug 2007

New TLR9 agonists patent for Dynavax Technologies

Dynavax Technologies Corporation has announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.

17 Aug 2007

Reducing inflammation plays key role in type 1 diabetes therapy

Researchers at Beth Israel Deaconess Medical Center (BIDMC) have found that a triple combination therapy consisting of both tolerance-inducing and anti-inflammatory properties is successful in abolishing adverse autoimmunity against insulin-producing cells in a mouse model of Type 1 diabetes.

1 Aug 2007

Restless legs syndrome simulator

Restless legs syndrome (RLS) remains a common, yet often undiagnosed, neurological sensorimotor disorder, despite many years of research and increased disease recognition.

20 Jul 2007

COPD patients taking inhaled steroids are at greater risk for severe pneumonia

Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly being prescribed inhaled corticosteroids to control exacerbations of the disease, but a new study finds that the anti-inflammatory drugs increase the chances that these patients will be hospitalized for pneumonia.

17 Jul 2007

Scientists take exciting approach for attacking cancers

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials.

10 Jul 2007

Abiraterone reduces levels of prostate specific antigen

For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new drug candidate that inhibits production of male hormones anywhere in the body is showing promise in early trials.

9 Jul 2007

Promising new therapy for protecting the fertility of women with cancer

A promising new therapy for protecting the fertility of women with cancer and auto-immune diseases such as lupus was revealed at the 23rd annual conference of the European Society of Human Reproduction and Embryology.

4 Jul 2007

SYMBICORT now available in the U.S. for asthma

AstraZeneca has announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

26 Jun 2007

SYMBICORT trial shows improved quality of life with asthma

New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo.

24 May 2007

Drug treatment slows decline in lung function in COPD patients

Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference, on Tuesday, May 22.

22 May 2007

Clinical trial data for Perforomist Inhalation solution

Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).

22 May 2007

New breast cancer treatment may dispense with the need for chemotherapy

According to the latest research new hormone therapy drugs designed to treat breast cancer may dispense with the need for chemotherapy thus avoiding the nasty side effects associated with the treatment.

21 May 2007

Hormone treatment could cut need for chemo in some younger breast cancer patients

Around 5,500 pre-menopausal breast cancer patients could be offered a hormone drug that is shown to be as effective as traditional chemotherapy - and so avoid potential infertility and long-term menopausal side effects - according to a Cancer Research UK report published in The Lancet.

20 May 2007

FDA approves Dey, L.P.'s NDA for chronic obstructive pulmonary disease inhalation solution

Dey, L.P. has announced that the Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Perforomist (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

15 May 2007

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Rotigotine is a drug not previously approved in the United States. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

10 May 2007